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Objectives: The objective of this study was to estimate the association between tocilizumab or cortico-
steroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a
hyperinflammatory state according to clinical and laboratory parameters.
Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19
and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with
tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC),
combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days.
Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calcu-
lated. Propensity scores were used as confounders, matching variables and for the inverse probability of
treatment weights (IPTWs).
Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy,
respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%),
27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio
for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22e0.47; p < 0.001) for tocili-
zumab, 0.82 (0.71e1.30; p 0.82) for IHDC, 0.61 (0.43e0.86; p 0.006) for PDC, and 1.17 (0.86e1.58; p 0.30)
for combination therapy. Other applications of the propensity score provided similar results, but were
not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW
analysis (0.07; 0.02e0.17; p < 0.001).icio de Enfermedades Infecciosas, Hospital Universitario Virgen Macarena, Avda Dr Fedriani 3, 41009 Seville. Spain.
.
mentioned in the Appendix section.
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should be prioritized for randomized trials in this situation. Jesús Rodríguez-Ba~no, Clin Microbiol
Infect 2021;27:244
© 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The clinical spectrum of coronavirus disease 2019 (COVID-19)
associated with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) varies from asymptomatic disease to severe pneu-
monia and death [1,2]. Increased serum concentrations of inflam-
matory and coagulation markers (including C-reactive protein
(CRP), ferritin, and D-dimer) and proinflammatory cytokines (such
as IL-2R, IL-6, IL-10, and TNF-a) have been associated with disease
severity in COVID-19 [3,4]. These findings indicate that a hyper-
inflammatory state may play a crucial role in severe cases of COVID-
19, as in other coronaviruses [5].
Regarding treatment of COVID-19, so far remdesivir is the only
antiviral that has shown some efficacy [6]. Because of the dysre-
gulated immune response characteristic of severe COVID-19, it is
conceivable that immunosuppressant drugs may have some effect
in selected patients. Despite the fact that some guidelines have
recommended against the use of corticosteroids [7,8], dexameth-
asone (6 mg/day) in the RECOVERY trial reduced mortality among
those receiving either invasive mechanical ventilation or oxygen
alone [9]. Other host response modifiers under investigation
include tocilizumab, a recombinant humanized anti-human IL-6
receptor [10], for which some comparative observational studies
have been reported [11e14].
Observational studies may help in the design of randomized
trials of immunomodulatory agents for the treatment of severe
COVID-19 by providing an estimation of their potential effects and
identifying potential candidates for these therapies. The objective
of this study was to provide an observational estimation of the
association between tocilizumab/corticosteroids and outcome in
non-intubated patients, specifically in thosewith data suggestive of
a hyperinflammatory state, within a large nationwide clinical
cohort of patients with COVID-19 to test the hypothesis that these
drugs might be associated with a reduced risk of intubation or
death.Methods
Design, patients and procedures
The SAM-COVID study is a retrospective cohort study nested in
the COVID19@Spain cohort (NCT04355871), in which consecutive
patients admitted to Spanish hospitals because of COVID-19
(confirmed by PCR in nasopharyngeal swab or lower respiratory
tract sample) from February 2nd to March 31st 2020 were included
[15]. SAM-COVID was also registered (NCT04382781) before the
analysis started.
Adult patients from the COVID19@Spain cohort were eligible for
SAM-COVID if presenting on a specific date (day 0) with at least one
clinical criterion and one laboratory criterion suggestive of a
hyperinflammatory state. Clinical criteria were (a) temperature
38C and (b) increase in oxygen support required to achieve O2
saturation >92%. Laboratory criteria were (a) ferritin >2000 ng/mL
or increase >1000 ng/mL since admission, (b) D-dimers >1500 mg/
mL (or doubled in 24 h), and (c) IL6 >50 pg/mL. Investigators fromthe COVID@Spain cohort sites were asked to further review the
charts of patients by assessing daily clinical and laboratory data,
and to provide additional information. Exclusion criteria were (a)
being under mechanical ventilation at day 0, (b) occurrence of the
primary endpoint in 2 day after day 0 (in order to avoid immortal
time bias), (c) written decision to avoid any escalation in medical
treatment before day 0, (d) previous use of systemic corticosteroids,
tocilizumab, other immunomodulatory drugs or immunoglobulins,
and (e) treatment with immunomodulatory drugs other than cor-
ticosteroids or tocilizumab, or with immunoglobulins during the
first 48 h after day 0. In addition, day 0 must have been before
March 31 to assure 21 days of follow-up when the database was
locked. Sixty hospitals participated in this study. The database was
monitored for missing data and inconsistencies.Variables
The main endpoint was intubation or death, whichever
happened first; follow-up was 21 days. Patients were censored on
the last day of contact if discharged before day 21. Secondary out-
comes were death, rates of secondary bacterial infection, digestive
tract bleeding, and proportion of patients with a score of 3 in a
seven-point ordinal scale at day 21 (1, not hospitalized; 2, hospi-
talized without supplemental oxygen; 3, hospitalized with sup-
plemental oxygen; 4, hospitalized and requiring supplemental
oxygen with a high nasal flow cannula or non-invasive ventilation;
5, hospitalized and requiring mechanical ventilation; 6, hospital-
ized and requiring extracorporeal membrane oxygenation (ECMO)
or invasive mechanical ventilation with amine support; and 7,
death).
The main treatments after day 0 were with tocilizumab,
intermediate-high dose corticosteroids (IHDC), pulse dose corti-
costeroids (PDC), combination therapy with tocilizumab and cor-
ticosteroids, or no treatment. In order to try to mimic the exposure
as in a randomized trial and intention-to-treat analysis, we classi-
fied exposure to treatment arms in the primary analysis as follows:
patients were assigned to tocilizumab, IHDC or PDC if administered
in 2 days after day 0; patients receiving both tocilizumab and
corticosteroids in the first 2 days were assigned to the combination
treatment group, while patients not receiving any of these drugs
were assigned to the non-treatment arm. Patients who started
treatment with the above drugs in days 3 and 4were excluded from
the primary analysis, as it would be debatable to which arm they
should be assigned, and to avoid immortal time bias; however,
these patients were included in a sensitivity analysis in which
treatments were considered as time-dependent variables. Corti-
costeroid treatment was classified as PDC if  250 mg of methyl-
prednisolone or equivalent per day were administered, or as IHDC
otherwise. Other variables collected are included in Table 1. The
data were obtained from the patients' charts. An electronic case
report was built using REDCap electronic data capture tools [16].
Missing values were classified as a separate category in the
analyses.
The study was approved by the University hospitals Virgen
Macarena and Virgen del Rocío ethic committee which waived the
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Age, median years (IQR) 69 (59e76) 66 (56e72) 0.10 71 (62e76) 0.05 71 (60e76) 0.24 65 (58e74) 0.01
Female gender 106/343
(30.9)
24/64 (27.3) 0.50 33/116 (28.4) 0.61 21/78 (26.9) 0.48 42/149 (28.1) 0.54
Caucasian ethnicity 316/338
(93.5)
80/87 (92.0) 0.61 110/113 (97.3) 0.12 75/78 (96.2) 0.37 132/147 (89.8) 0.15
Comorbidities:
Cardiac disease 62/344 (18.0) 11/88 (12.5) 0.21 21/117 (17.9) 0.98 11/78 (14.1) 0.40 17/150 (11.3) 0.06
Hypertension 175/344
(50.9)
30/88 (34.1) 0.005 61/117 (52.1) 0.81 42/78 (53.8) 0.63 73/151 (48.3) 0.60
Chronic pulmonary disease 37 (10.8) 6/88 (6.8) 0.27 18/117 (15.4) 0.18 9/78 (11.5) 0.84 17/151 (11.3) 0.86
Severe chronic renal insufficiency 13 (3.8) 0/87 (0) 0.08 3/116 (2.6) 0.77 5/78 (6.4) 0.34 1/151 (0.7) 0.07
Liver cirrhosis 5/337 (1.5) 1/87 (1.1) 1.0 1/117 (0.9) 1.0 1/78 (1.3) 1.0 0/151 (0) 0.33
Malignancy 15/344 (4.4) 1/88 (1.1) 0.09 4/117 (3.4) 0.39 4/78 (5.1) 0.89 2/151 (1.3) 0.07
HIV infection 0/344 (0) 1/88 (1.1) 0.20 0/117 (0) d 0/78 (0) d 0/151 (0) d
Obesity 39/309 (11.4) 12/78 (14.3) 0.54 19/111 (17.1) 0.16 5/68 (7.4) 0.22 23/134 (17.2) 0.20
Diabetes mellitus 72/344 (20.9) 15/88 (17.0) 0.41 29/117 (24.8) 0.38 12/78 (15.4) 0.26 26/151 (17.2) 0.34
Dementia 14/344 (4.1) 1/88 (1.1) 0.18 4/117 (2.4) 0.75 0 0.08 0/151 (0) 0.01
Admission data:
Percentage oxygen saturation with
room air, mean (SD)
92.6 (6.0) 92.1 (6.4) 0.51 91.0 (5.1) 0.1 90.0 (5.6) 0.001 91.8 (5.2) 0.19




67/78 (85.9) 0.37 91/102 (89.2) 0.07 52/69 (82.6) 0.84 132/131 (87.0) 0.16
Lymphocytes/mL, mean (SD) 1069 (1049) 989 (814) 0.67 1313 (1952) 0.09 1244 (1753) 0.25 948 (520) 0.17
LDH in U/L, mean (SD) 388 (158) 392 (143) 0.39 388 (152) 0.20 385 (119) 0.39 408 (166) 0.73
C-reactive protein in mg/L, mean (SD) 112 (101) 118 (100) 0.64 124 (107) 0.28 118 (99) 0.63 112 (99) 0.96
Antiviral treatment before day 0:
Lopinavir/ritonavir 242/335
(72.2)
71/87 (81.6) 0.07 86/117 (73.5) 0.79 59/78 (75.6) 0.49 111/151 (73.5) 0.77
Hydroxychloroquine 319/335
(94.4)
86/88 (97.7) 0.27 104/117 (88.9) 0.04 73/78 (93.6) 0.84 144/151 (95.4) 0.65
Remdesivir 3/334 (0.9) 0/88 (0) 1.0 0/117 (0) 0.52 0/78 (0) 1.0 0/151 (0) 0.55
Azithromycin 223/337
(66.2)
65/88 (73.9) 0.16 79/117 (67.5) 0.79 48/78 (61.5) 0.58 116/147 (78.9) 0.005
Interferon b 71/332 (21.4) 24/86 (27.9) 0.19 25/116 (21.6) 0.97 12/78 (15.4) 0.84 27/151 (17.9) 0.85
Data on day 0:
Median days of symptoms (IQR) 8 (6e11) 10 (8e13) 0.02 10 (7e12) 0.05 6 (9e12) 0.22 11 (8e13) <0.001
Median days from admission to day
0 (IQR)
1 (0e4) 3 (1e5) 0.001 2 (1e4) 0.08 2 (1e5) 0.21 3 (1e5) 0.001
Fever 202/344
(58.7)
42/88 (47.7) 0.06 65/117 (55.6) 0.54 38/78 (48.7) 0.10 77/151 (51.0) 0.11
Worsening in oxygen requirements 230/344
(66.9)
81/88 (92.0) <0.001 87/117 (74.4) 0.13 70/78 (89.7) <0.001 136/151 (90.1) <0.001
Ferritin >2000 ng/mL 95/194 (49.0) 19/59 (32.2) 0.02 34/78 (43.6) 0.42 29/62 (46.8) 0.76 51/100 (51.0) 0.74
D-dimers >1500 mg/mL 192/311
(61.7)
43/82 (52.4) 0.12 55/112 (49.1) 0.02 40/73 (54.8) 0.27 78/140 (55.7) 0.24
IL6 >50 pg/mL 100/132
(75.8)
57/59 (96.6) <0.001 47/53 (88.7) 0.04 26/37 (70.3) 0.49 81/95 (85.3) 0.07
Oxygen support at day e1: 0.001 0.001 0.001 <0.001
Nasal cannula or mask 282/340
(82.9)
57/88 (63.6) 82/117 (70.1) 51/78 (65.3) 71/149 (48.3)
Mask with reservoir bag 46/340 (13.5) 26/88 (29.2) 30/117 (25.6) 25/78 (32.1) 65/149 (43.0)
High-flow nasal cannula 10/340 (2.9) 3/88 (3.4) 1/117 (0.9) 1/78 (1.3) 5/149 (3.3)




69/88 (80.2) 0.22 93/117 (79.5) 0.11 57/78 (73.1) 0.88 115/150 (76.7) 0.27
Anticoagulant dose 36/340 (10.6) 12/88 (14.0) 0.44 17/117 (14.5) 0.23 16/78 (20.5) 0.01 26/150 (17.3) 0.03
Immunomodulatory drugs after day 4:
Corticosteroids, low dose 39/344 (11.3) 11/88 (12.5) 0.71 d d 35/78 (44.9) <0.001 d d
Corticosteroids, high dose 26/344 (7.5) 6/88 (6.8) 1.0 0/117 (0) <0.001 d d d d
Tocilizumab 22/344 (6.5) d d 7/117 (5.9) 0.87 10/78 (12.8) 0.08 d d
IQR: interquartile range.
a For tocilizumab versus no treatment.
b For corticosteroids, high-intermediate dose versus no treatment.
c For corticosteroids, pulse dose versus no treatment.
d For combination versus no treatment.
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nature of the study. The study is reported according to STROBE
recommendations (Supplementary Material Table S1).Statistical analysis
Patients classified as receiving no treatment were compared to
those treated with tocilizumab, IHDC, PDC, or combination treat-
ment for baseline variables at admission and day 0 using Student t-
test or ManneWhitney U test for continuous variables and c2 or
Fisher test for categorical variables, as appropriate. The association
of treatment with time-related endpoints was analysed using
KaplaneMeier curves and Cox regression analysis. The sites were
included as a random effect variable in the models. Propensity
scores for receiving early treatment with tocilizumab, IHDC, PDC or
combination therapy instead of no treatment were calculated by
performing non-parsimonious multivariate logistic regression
models by including all measured potential predictors for treat-
ment. The ability of the propensity scores to predict the observed
data was calculated by the area under the receiver operating
characteristic curve (AUROC) with 95% confidence intervals (95%
CIs). The propensity scores were used to calculate the inverse
probability of treatment weight (IPTW) in Cox analysis, as a
confounder and as a matching variable (treated/not treated, 1:2
ratio), using the nearest neighbour method with a tolerance <5%.
When the proportional hazards assumptions were not fulfilled for
performing Cox regression, logistic regression (conditional if
matched analyses) was used. Multivariate models with forward
addition of different variables to the model adjusted by the pro-
pensity score were also performed, after excluding collinearity.
Sensitivity analyses were performed by including patients who
started treatments on days 3 and 4, and considering exposure to
study drugs as time-dependent variables, counting the days until
the first dose of the drug was administered from day 0. All analyses
were performed using IBM SPSS Statistics v26 and R.Results
Overall, 1014 eligible patients were identified; 778 were
included in the primary analysis (Fig. 1), including 344 in the no-
treatment arm, 88 treated with tocilizumab, 117 with IHDC, 78
with PDC, and 151 with combination treatment (all received toci-
lizumab, 77 received IHDC and 74 PDC).
The features of the patients are shown in Table 1. Overall, pa-
tients in the treatment arms needed a higher level of oxygen sup-
port at day 0 than those in the no-treatment arm. The proportion of









Endpoint in ≤2 day: 109
Treatment starded on days 3-41: 69
Second drug added in ≤2 days2: 58
Fig. 1. Flowchart of patients incluthe tocilizumab and IHDC arms; it was the only laboratory criterion
for inclusion in 24.4% of the patients. By contrast, ferritin and D-
dimers were less frequently elevated in the tocilizumab and IHDC
arms, respectively. Details regarding the drugs dosing are shown in
the Supplementary Material Table S2.
The crude outcomes of patients according to treatment arm are
shown in Table 2, and crude KaplaneMeier curves for the primary
endpoint are shown in Fig. 2. The proportional hazard assumption
was not fulfilled in the comparison of IHDC and combination versus
no treatment, and logistic regression was used for these compari-
sons. The propensity score-adjusted associations of treatments for
the primary endpoint are shown in Table 3, which also includes the
variables used for the propensity score calculation. The comparison
of features of the propensity score-matched patients are shown in
the Supplementary Material Table S3. The IPTW-adjusted
KaplaneMeier curves for tocilizumab and PDC are shown in the
SupplementaryMaterial Fig. S1. Overall, tocilizumabwas associated
with lower hazard for the primary endpoint in all adjusted ana-
lyses; the estimations for PDC were all on the protective side but
were significant only in the IPTW model. IHDC and combination
therapy were not associated with significant risk differences.
Addition of other variables to the models and sensitivity analyses
considering treatments as time-dependent variables provided no
significant changes in the estimations.
Regarding the secondary outcomes, the crude estimations are
shown in Table 2. The proportion of patients with a score 3 on the
7-point scale at day 21 was higher in the tocilizumab arm. No dif-
ferences were seen in the rates of secondary bacterial infection or
gastrointestinal bleeding. Regarding mortality, the KaplaneMeier
curves (crude data) are shown in the Supplementary Material
Fig. S2. The adjusted analyses are shown in Table 3, and the
IPTW-adjusted KaplaneMeier curves are in the Supplementary
Material Fig. S3. Tocilizumab was associated with a lower hazard
of death in all adjusted models. PDC was nearly associated with a
lower risk of death only in the IPTW model; neither IHDC nor
combination therapy could demonstrate a significant association
with mortality (Table 3).Discussion
In this observational, multicentre, propensity score-adjusted
study, tocilizumab was associated with lower hazards of intuba-
tion or death in patients with COVID-19 presenting with clinical
and laboratory data suggestive of a hyperinflammatory state. The
association with PDC was also significant in the analysis with the











ded in the primary analysis.
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Primary outcomee 69/344 (20.1) 10/88 (11.4) 0.05 27/117 (23.1) 0.57 12/78 (15.4) 0.28 40/151 (26.5) 0.13
Median follow-up without the
endpoint, days (IQR)
20 (13e21) 21 (16e21) 0.01 21 (16e21) 0.56 21 (12.21) 0.55 20 (11e21) 0.87
Scale at day 21 n ¼ 344 n ¼ 88 d n ¼ 117 d n ¼ 78 d n ¼ 151 d
1 253 (73.5) 70 (79.5) 80 (68.4) 55 (70.5) 100 (66.2)
2 10 (2.9) 2 (2.3) 4 (3.4) 2 (2.6) 8 (5.3)
3 16 (4.7) 8 (9.1) 8 (6.8) 8 (10.3) 14 (9.3)
4 4 (1.2) 0 0 1 (1.3) 1 (0.7)
5 19 (5.5) 6 (6.8) 2 (1.7) 4 (5.1) 9 (6.0)
6 1 (0.3) 0 1 (0.9) 0 19 (6.0)
7 (death) 41 (11.9) 2 (2.3) 0.004 22 (18.8) 0.08 8 (10.3) 0.84 19 (12.6) 0.88
Scale 3 279 (81.1) 80 (90.9) 0.02 92 (78.6) 0.56 65 (83.3) 0.64 122 (80.8) 0.93
Digestive tract bleeding 2/341 (0.6) 1/88 (1.1) 0.49 1/115 (1.4) 1.0 1/74 (1.4) 0.44 3/150 (2.0) 0.16
Secondary bacterial infection 36/339 (10.3) 11/88 (12.5) 0.57 10/115 (8.7) 0.72 8/75 (10.7) 1.0 18/150 (12.0) 0.64
IQR, interquartile range.
a For tocilizumab versus no treatment.
b For corticosteroids, intermediate-high dose versus no treatment.
c For corticosteroids, pulse dose versus no treatment.
d For combination versus no treatment.
e P values obtained by univariate Cox regression except for combination therapy, for which logistic-regression was used.
Fig. 2. Probability of remaining event-free (intubation or death) according to the different treatments used, in comparison with no treatment (crude analyses). (A) Tocilizumab. (B)
Corticosteroids, intermediate-high dose. (C) Corticosteroids, pulse dose. (D) Combination therapy.
J. Rodríguez-Ba~no et al. / Clinical Microbiology and Infection 27 (2021) 244e252248informative. On the other hand, we could not find a significant
association between IHDC or combination therapy and outcomes.
One of the problems in observational studies is the assignment
of patients to treatment arms. In this study we mimicked exposure
and intention-to-treat analysis in randomized trials, in which
treatments are typically started in 2 days, and we excluded pa-
tients for whom the endpoint was reached in such a period or
patients starting treatment in days 3 and 4, in order to avoid
immortal time bias. In fact, sensitivity analysis which includedpatients treated on days 3e4 and considered exposure to drugs as
time-dependent variables did not show different results, suggest-
ing that immortal time bias was not affecting the estimations.
We used a ‘hard’ composite primary outcome including intu-
bation or death because some patients may be candidates for
additional medical treatment but not for intubation due to their
previous conditions. Anyhow, the results were similar when only
mortality or the proportions of patients with a score of 3 in the 7-
point scale were considered. Our data were not specific for adverse
Table 3
Estimation of the association of treatments with the primary endpoint (time until intubation or death) and with mortality in the different models. Adjusted models used
specific propensity scoresa for receiving each drug
Intubation or death
Tocilizumab versus no treatment HR (95%CI) p
Crude 0.52 (0.27e1.01) 0.05
With propensity score 0.32 (0.15e0.67) 0.003
Inverse probability of treatment weights 0.32 (0.22e0.47) <0.001
Matched cases 0.42 (0.19e0.92) 0.03
Time-dependent variable with propensity score 0.36 (0.17e0.75) 0.007
Corticosteroids, intermediate-high dose versus no treatment OR (95%CI) p
Crude 1.17 (0.71e1.95) 0.52
With propensity score 0.83 (0.48e1.45) 0.53
Inverse probability of treatment weights 1.00 (0.72e1.41) 0.96
Matched cases 0.80 (0.42e1.41) 0.50
Time-dependent variable with propensity score 0.95 (0.59e1.53) 0.84
Corticosteroids, pulse dose versus no treatment HR (95%CI) p
Crude 0.71 (0.38e1.32) 0.28
With propensity score 0.71 (0.36e1.38) 0.31
Inverse probability of treatment weights 0.61 (0.43e0.86) 0.006
Matched cases 0.69 (0.32e1.51) 0.36
Time-dependent variable with propensity score 0.79 (0.41e1.53) 0.50
Combination therapy versus no treatment OR (95%CI) p
Crude 1.41 (0.90e2.21) 0.13
With propensity score 1.20 (0.71e2.01) 0.48
Inverse probability of treatment weights 1.17 (0.86e1.58) 0.30
Matched cases 1.71 (0.88e3.31) 0.10
Time-dependent variable with propensity score 1.17 (0.74e1.84) 0.48
DEATH
Tocilizumab versus no treatment HR (95%CI) p
Crude 0.17 (0.04e0.70) 0.01
With propensity score 0.12 (0.02e0.56) 0.007
Inverse probability of treatment weights 0.07 (0.02e0.17) <0.001
Matched cases 0.22 (0.05e0.96) 0.04
Corticosteroids, intermediate-high dose versus no treatment HR (95%CI) p
Crude 1.66 (0.99e2.79) 0.05
With propensity score 1.16 (0.66e2.03) 0.59
Inverse probability of treatment weights 1.21 (0.62e2.35) 0.56
Matched cases 1.02 (0.66e1.58) 0.90
Corticosteroids, pulse dose versus no treatment OR (95%CI) p
Crude 0.80 (0.35e1.81) 0.59
With propensity score 0.74 (0.31e1.77) 0.51
Inverse probability of treatment weights 0.64 (0.24e1.04) 0.06
Matched cases 0.67 (0.24e1.84) 0.43
Combination therapy versus no treatment OR (95%CI) p
Crude 1.03 (0.57e1.85) 0.90
With propensity score 1.31 (0.67e2.54) 0.42
Inverse probability of treatment weights 1.17 (0.75e1.64) 0.57
Matched cases 1.36 (0.58e3.21) 0.47
a Propensity scores were calculated including age, gender, ethnicity, comorbidities (cardiac disease, hypertension, chronic pulmonary disease, chronic renal disease, liver
cirrhosis, malignancy, diabetes mellitus, obesity, HIV infection), laboratory data (lymphocytes, lactate dehydrogenase, alanine aminotransferase, ferritin, D-dimers, IL-6),
previous treatments, radiographic findings, 7-point scale and type of oxygen requirement. Their predictive ability for observed data are 0.79 (95%CI: 0.74e0.85) for tocili-
zumab, 0.72 (0.68e0.77) for corticosteroids, intermediate-high dose, 0.77 (0.71e0.82) for corticosteroids, pulse dose, and 0.81 (0.77e0.85) for combination therapy.
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more detail in future studies.
Regarding confounders, we used propensity scores in different
ways in order to control for the indication bias. Because the IPTW
provides a higher weight to patients treated with the drug of in-
terest when having a lower probability of receiving that drug, the
confidence intervals are reduced, while in the case of tocilizumab
all models showed a significant association with improved out-
comes; it was only with this analysis that PDC showed a significant
association. We hypothesize that the lack of significant association
with other analysis for PDC might be due to insufficient statistical
power.
We found four observational comparative studies with tocili-
zumab in non-intubated patients with severe COVID-19 pneu-
monia. In one of them, 32 patients treated with tocilizumab were
compared to 33 controls; patients treated with tocilizumab showed
numerically lower mortality but the differences were not signifi-
cant [11]. In another, treatment with tocilizumab (62 patients) wasassociated with better adjusted survival and a favourable clinical
course in comparisonwith standard treatment (23 patients) [12]. A
third study compared 179 patients treated with tocilizumab (88
intravenously) with 365 receiving standard of care in three Italian
centres; tocilizumab was associated with a lower adjusted risk of
invasivemechanical ventilation or death [13]. Finally, a fourth study
found lower mortality in non-intubated patients, but adjusted an-
alyses were not performed [14]. Several randomized trials with
tocilizumab are ongoing; a press release by the promoter of the
COVACTA trial reported that it did not show superiority over pla-
cebo in the primary endpoint (data not published) [17]. However,
inclusion criteria in this trial did not consider data suggestive of a
hyperinflammatory state [18].
Regarding corticosteroids, recent meta-analyses showed con-
tradictory results [19,20]. In these reviews, the dosing of cortico-
steroids was not specified. The results from a quasi-experimental
study suggested that early administration of 0.5e1 mg/kg of
methylprednisolone for 3 days is associated with a protective effect
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ventilation or death [21], while a cohort study including 35 pro-
pensity score-matched couples of patients with and without cor-
ticosteroids (methylprednisolone, 40e50 mg/day) found no
significant differences in outcomes [22]. A preliminary report of
data from the RECOVERY randomized trial found that dexametha-
sone 6 mg/day (equivalent to methylprednisolone 30 mg) resulted
in lower mortality among patients requiring oxygen or mechanical
ventilation; the effect was more prominent in patients under me-
chanical ventilation [9]. It should be noted that corticosteroids in
our study were used at higher doses in most patients, and were
started only once the patients had developed a hyperinflammatory
state based on clinical and laboratory data. We found no studies
with pulse dose corticosteroids. While our results in this group are
less clear, we think they support the development of a randomized
trial in this clinical situation. We did not find any studies investi-
gating the combination of tocilizumab and corticosteroids; the
negative results in our study should be takenwith caution since this
was a heterogeneous group including different timing and dosing
of both drugs. We could not perform more detailed analysis in this
group since the numbers of patients in the subgroups were too low.
This study has several limitations. First, control for confounders
in any observational study may be incomplete despite all efforts.
Second, even though we registered the study design before per-
forming any analysis, the criteria for assignment to study armswere
not specified; however, theywere decided before the analyses were
performed. Third, a wide range of dosing regimens were used in the
corticosteroid arms. Fourth, the investigators were not blinded for
the exposure; however, we used hard outcomes and included
consecutive cases. Fifth, the assessment of adverse events was not
complete. And sixth, the study was performed during the first
month of the pandemic in Spain; management may have changed
afterwards.
The study also has some strengths, including the multicentre
participation, the use of specific exposure definitions and advanced
analyses for observational studies, and representativeness of real-
life patients.
In conclusion, these findings suggest that testing tocilizumab
should be prioritized for being tested in randomized trials targeting
patients with data suggestive of a hyperinflammatory state, and
that pending further evidence, it should be considered with caution
in the treatment of this condition if participation in randomized
trials is not possible. Additional data are needed for tocilizumab in
patients who previously received corticosteroids, which might be
the standard of care now. The results for PDC were less consistent
but are also encouraging.
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